{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0001548\nAge: 68\nGender: Female\nSample ID: P-0001548-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Pancreatic Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 60.0%\n=============\nDNA Variants:\nKRAS c.35G>T (p.G12V) - in 46.00% of 1251 reads\nTP53 c.838A>G (p.R280G) - in 53.00% of 703 reads\nCNA Data:\nCDKN2B - Homozygous Deletion\nCDKN2A - Homozygous Deletion\nCDKN2Ap14ARF - Homozygous Deletion\nCDKN2Ap16INK4A - Homozygous Deletion\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"FOLFIRINOX (fluorouracil, leucovorin, irinotecan, oxaliplatin)\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": {\n      \"KRAS c.35G>T (p.G12V)\": \"KRAS mutation common in pancreatic cancer; no targeted therapies approved yet\",\n      \"TP53 c.838A>G (p.R280G)\": \"TP53 mutation; no targeted therapy currently available\",\n      \"Homozygous deletions of CDKN2A, CDKN2B, CDKN2Ap14ARF, CDKN2Ap16INK4A\": \"Loss of tumor suppressor genes; may influence response but no direct targeted therapy\"\n    },\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-therapies-pancreatic-cancer\"\n  }\n}"
}